Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00797953
Other study ID # T89-005-0003-US
Secondary ID
Status Completed
Phase Phase 2
First received November 24, 2008
Last updated December 10, 2012
Start date February 2007
Est. completion date January 2010

Study information

Verified date December 2012
Source Tasly Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.


Description:

T89 is a modernized and industrialized version of a traditional Chinese herbal medicine. T89 was approved for marketing as a drug, for the treatment of chronic stable angina pectoris due to coronary heart disease, by the State Food and Drug Administration (SFDA) of China in 1993. There were more than 2 billion doses have been prescribed or used, in about 10,000,000 subjects, in short or long-term administration worldwide.

The product is also marketed, as a drug, in Russia, South Korea, Mongolia, Singapore, Vietnam, and South Africa. The current study is to determine the anti-angina effect and dose response of T89 in patients with chronic stable angina pectoris in the United States.

T89 consists of Danshen (Radix Salviae Miltiorrhizae, RSM) and Sanqi (Radix Notoginseng, RN) as active constitutes, and using Borneol as transporting enhancer.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date January 2010
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Patient must be between the ages of 18 and 80 years.

2. Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.

3. Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation.

4. Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph (ECG) changes.

5. Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)

6. Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0

7. All anti-angina regimen (except short-acting nitroglycerin, and one beta-blocker or calcium channel blocker), warfarin or other oral anticoagulants which were used prior to this initial visit can be discontinued.

8. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the verbal rating scales and diary cards.

9. Patient must be able to give voluntary written informed consent.

Exclusion Criteria:

1. With contraindication to perform treadmill Exercise Tolerance Test (ETT).

2. Pre-exercise ST-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff-Parkinson-White (WPW) syndrome or other factors that could interfere with exercise electrocardiograph interpretation.

3. Clinically significant arrhythmias or atrioventricular conduction block greater than first degree.

4. Clinically significant co-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication.

5. History of congestive heart failure, unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry.

6. History of bleeding diathesis, or is on warfarin.

7. Implanted pacemaker.

8. Aspirin and/or statins started less than 14 days prior to the signing of informed consent.

9. Pregnancy or lactation.

10. Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and allow only short-acting nitroglycerin and one beta-blocker or calcium channel blocker.

11. Clinical trials/experimental medication:

- Participation in any other clinical trial or receipt of an investigational drug within 90 days prior to initial visit.

- Those patients unable, in the opinion of the investigator, to comply fully with the trial requirements.

- Previous participation in this study.

12. Substance abuse. Patients with a recent history (within the last 2 years) of alcoholism or known drug dependence.

13. Patient is a family member or relative of the study site staff.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
T89
A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.

Locations

Country Name City State
United States Alexandria Cardiology Clinic Alexandria Louisiana
United States Great Lakes Research Group, Inc Bay City Michigan
United States Robert M. Karns, A Medical Corporation Beverly Hills California
United States Three Rivers Medical Associates Columbia South Carolina
United States Inland Heart Doctors Corona California
United States East Texas Cardiology Houston Texas
United States Northwest Houston Cardiology Houston Texas
United States Sunrise Medical Research Lauderdale Lakes Florida
United States Gemini Scientific, LLC Madison Wisconsin
United States Cardiovascular Research Center of South Florida Miami Florida
United States National Clinical Research-Norfolk, Inc Norfolk Virginia
United States Oklahoma Cardiovascular & Hypertension Oklahoma Oklahoma
United States Northwest Heart Center Tomball Texas
United States Paradigm Clinical, Inc. Tucson Arizona
United States Marc Kozinn Associates Williamsville New York

Sponsors (1)

Lead Sponsor Collaborator
Tasly Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Exercise Duration (TED) change from screen baseline value in Exercise Tolerance Test (ETT) on Standard Bruce Protocol at trough drug levels at the end of the 4th and 8th week of treatment compared to placebo. 12 weeks
Secondary Frequency of weekly angina episodes 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT02773615 - CT Perfusion Added to CT Angiography
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Terminated NCT02548611 - Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention Phase 4
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT02440893 - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed NCT01486030 - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
Completed NCT01425359 - Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina Phase 4
Completed NCT01604486 - Natural Ischaemic Preconditioning Before First Myocardial Infarction N/A
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Completed NCT00131183 - Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Phase 4
Completed NCT00184444 - Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients N/A
Completed NCT00235404 - Randomized Controlled Trial of Health Care to Elderly Patients. N/A
Terminated NCT00157742 - Comparison of SCS and PMR in Patients With Refractory Angina Pectoris Phase 4
Completed NCT00000510 - Platelet-Inhibitor Drug Trial in Coronary Angioplasty Phase 3
Completed NCT00005148 - Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships N/A
Not yet recruiting NCT03657758 - Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO] Phase 4
Completed NCT05050773 - Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)
Completed NCT00093223 - A Safety Study of ABI-007 for In-Stent Restenosis Phase 2
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A

External Links